Next generation CDK4 + CDK2 selective inhibitor in HR+ HER2- metastatic breast cancer

Next generation CDK4 + CDK2 selective inhibitor in HR+ HER2- metastatic breast cancer

What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Pe...Подробнее

What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Pe...

Dr. Mik Rinne on the First Promising CDK2 Inhibitor in Combination to Treat HR+/HER2- Breast CancerПодробнее

Dr. Mik Rinne on the First Promising CDK2 Inhibitor in Combination to Treat HR+/HER2- Breast Cancer

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 InhibitorsПодробнее

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors

CDK 4/6 Inhibitors for Patients with Recurrent ER+/HER2- Breast Cancer: 2023 Best of BreastПодробнее

CDK 4/6 Inhibitors for Patients with Recurrent ER+/HER2- Breast Cancer: 2023 Best of Breast

Treatment & Benefits of CDK 4/6 inhibitors in HR+/ HER2-ve MBC Clinical practice to real world dataПодробнее

Treatment & Benefits of CDK 4/6 inhibitors in HR+/ HER2-ve MBC Clinical practice to real world data

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current...Подробнее

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current...

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancerПодробнее

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancer

Dr. Accordino on the Utility of CDK4/6 Inhibitors in HR+/HER2– Breast CancerПодробнее

Dr. Accordino on the Utility of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

Key Takeaways from ESMO: CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast CancerПодробнее

Key Takeaways from ESMO: CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer

CDK4/6 inhibitors in early stage HR+/HER2- diseaseПодробнее

CDK4/6 inhibitors in early stage HR+/HER2- disease

Dr. Geoffrey Shapiro on the Role of CDK2 in Multiple Breast Cancer TypesПодробнее

Dr. Geoffrey Shapiro on the Role of CDK2 in Multiple Breast Cancer Types

Nancy Lin, MD, explores the role of CDK4/6 inhibitors in metastatic breast cancer managementПодробнее

Nancy Lin, MD, explores the role of CDK4/6 inhibitors in metastatic breast cancer management

CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancerПодробнее

CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer

Dr. Tolaney on Remaining Questions With CDK4/6 Inhibitors in HR+/HER2- Breast CancerПодробнее

Dr. Tolaney on Remaining Questions With CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Treatment benefit of CDK4/6 inhibitors in HR+/HER2- aBC in clinical trials and the real worldПодробнее

Treatment benefit of CDK4/6 inhibitors in HR+/HER2- aBC in clinical trials and the real world

CDK4/6 Inhibitors in HER2-Negative Breast Cancer Based on Phase III MONALEESA-7 TrialПодробнее

CDK4/6 Inhibitors in HER2-Negative Breast Cancer Based on Phase III MONALEESA-7 Trial

FirstWord Analyst Notes Ibrance and the next generation of CDK4/6 inhibitors – KOLs speak outПодробнее

FirstWord Analyst Notes Ibrance and the next generation of CDK4/6 inhibitors – KOLs speak out

Interactive Case: Choosing and Using CDK4/6 Inhibitors in Breast Cancer - Second-line TherapyПодробнее

Interactive Case: Choosing and Using CDK4/6 Inhibitors in Breast Cancer - Second-line Therapy

Interactive Case: Choosing and Using CDK4/6 Inhibitors in Breast Cancer - First-line TherapyПодробнее

Interactive Case: Choosing and Using CDK4/6 Inhibitors in Breast Cancer - First-line Therapy